AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease.
AGAP2-AS1
Biomarker
Low-risk
RNA-seq
ccRCC
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
20 Dec 2021
20 Dec 2021
Historique:
received:
25
08
2021
accepted:
06
12
2021
entrez:
21
12
2021
pubmed:
22
12
2021
medline:
22
12
2021
Statut:
epublish
Résumé
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer and one of the most common cancers. While survival for localized ccRCC is good, the survival of metastatic disease is not, and thirty percent of patients with ccRCC develop metastases during follow-up. Although current scoring methods accurately identify patients at low progression risk, a small subgroup of those patients still experience metastasis. We therefore aimed to identify ccRCC progression biomarkers in "low-risk" patients who were potentially eligible for adjuvant treatments or more intensive follow-up. We assembled a cohort of ccRCC patients (n = 443) and identified all "low-risk" patients who later developed progressing tumors (n = 8). Subsequently, we performed genome-wide expression profiling from formalin-fixed samples obtained at initial surgery from these "low-risk" patients and 16 matched patients not progressing to recurrence with metastasis. The patients were matched for Leibovich sore, creatinine, age, sex, tumor size and tumor stage. Key results were confirmed with qPCR and external data from The Cancer Genome Atlas. Principal component analysis indicated that systematic transcriptomic differences were already detectable at the time of initial surgery. One thousand one hundred sixty-seven genes, mainly associated with cancer and immune-related pathways, were differentially expressed between progressors and nonprogressors. A search for a classifier revealed that overexpression of AGAP2-AS1, an antisense long noncoding RNA, correctly classified 23 of 24 samples, years (4.5 years average) in advance of the discovery of metastasis and without requiring larger gene panels. Subsequently, we confirmed AGAP2-AS1 gene overexpression by qPCR in the same samples (p < 0.05). Additionally, in external data from The Cancer Genome Atlas, overexpression of AGAP2-AS1 is correlated with overall unfavorable survival outcome in ccRCC, irrespective of other prognostic predictors (p = 2.44E-7). AGAP2-AS1 may represent a novel biomarker identifying high-risk ccRCC patients currently classified as "low risk" at the time of surgery.
Sections du résumé
BACKGROUND
BACKGROUND
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer and one of the most common cancers. While survival for localized ccRCC is good, the survival of metastatic disease is not, and thirty percent of patients with ccRCC develop metastases during follow-up. Although current scoring methods accurately identify patients at low progression risk, a small subgroup of those patients still experience metastasis. We therefore aimed to identify ccRCC progression biomarkers in "low-risk" patients who were potentially eligible for adjuvant treatments or more intensive follow-up.
METHODS
METHODS
We assembled a cohort of ccRCC patients (n = 443) and identified all "low-risk" patients who later developed progressing tumors (n = 8). Subsequently, we performed genome-wide expression profiling from formalin-fixed samples obtained at initial surgery from these "low-risk" patients and 16 matched patients not progressing to recurrence with metastasis. The patients were matched for Leibovich sore, creatinine, age, sex, tumor size and tumor stage. Key results were confirmed with qPCR and external data from The Cancer Genome Atlas.
RESULTS
RESULTS
Principal component analysis indicated that systematic transcriptomic differences were already detectable at the time of initial surgery. One thousand one hundred sixty-seven genes, mainly associated with cancer and immune-related pathways, were differentially expressed between progressors and nonprogressors. A search for a classifier revealed that overexpression of AGAP2-AS1, an antisense long noncoding RNA, correctly classified 23 of 24 samples, years (4.5 years average) in advance of the discovery of metastasis and without requiring larger gene panels. Subsequently, we confirmed AGAP2-AS1 gene overexpression by qPCR in the same samples (p < 0.05). Additionally, in external data from The Cancer Genome Atlas, overexpression of AGAP2-AS1 is correlated with overall unfavorable survival outcome in ccRCC, irrespective of other prognostic predictors (p = 2.44E-7).
CONCLUSION
CONCLUSIONS
AGAP2-AS1 may represent a novel biomarker identifying high-risk ccRCC patients currently classified as "low risk" at the time of surgery.
Identifiants
pubmed: 34930263
doi: 10.1186/s12935-021-02395-9
pii: 10.1186/s12935-021-02395-9
pmc: PMC8686242
doi:
Types de publication
Journal Article
Langues
eng
Pagination
690Subventions
Organisme : Helse Vest Regionalt Helseføretak
ID : 912167
Informations de copyright
© 2021. The Author(s).
Références
Cell. 2010 Feb 5;140(3):384-96
pubmed: 20096447
Scand J Clin Lab Invest. 2016 Sep;76(5):426-34
pubmed: 27173776
J Clin Oncol. 2019 Aug 10;37(23):2062-2071
pubmed: 31216227
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Genes Cancer. 2010 Feb 1;1(2):152-163
pubmed: 20871783
Cancer Biomark. 2010;9(1-6):461-73
pubmed: 22112490
Oncol Lett. 2020 Jun;19(6):3993-4001
pubmed: 32382344
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Int J Biol Macromol. 2019 May 1;128:521-530
pubmed: 30684575
Med Sci Monit. 2019 Mar 26;25:2211-2220
pubmed: 30910994
Aging (Albany NY). 2019 Jun 11;11(11):3811-3823
pubmed: 31186379
Urol Oncol. 2016 Mar;34(3):122.e1-7
pubmed: 26546482
Cell Death Dis. 2019 Feb 27;10(3):207
pubmed: 30814490
Med Sci Monit. 2019 Jun 24;25:4699-4704
pubmed: 31233485
Eur Urol. 2014 Jul;66(1):77-84
pubmed: 24613583
Eur Urol Focus. 2016 Dec 15;2(6):608-615
pubmed: 28723492
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
BMJ. 2004 Jul 24;329(7459):209-13
pubmed: 15271832
J Hematol Oncol. 2017 Feb 16;10(1):48
pubmed: 28209205
Kidney Cancer. 2018;2(1):23-29
pubmed: 30320241
Cell Death Dis. 2016 May 19;7:e2225
pubmed: 27195672
Eur Rev Med Pharmacol Sci. 2017 May;21(10):2392-2396
pubmed: 28617550
World J Urol. 2016 Aug;34(8):1087-99
pubmed: 26922650
Genome Biol. 2010;11(3):R25
pubmed: 20196867
J Immunol. 2013 Nov 1;191(9):4880-8
pubmed: 24078694
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
BJU Int. 2020 Apr;125(4):561-567
pubmed: 31955483
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Oncotarget. 2016 Nov 22;7(47):77225-77236
pubmed: 27764782
Scand J Urol. 2015 Jun;49(3):205-10
pubmed: 25423093
J Exp Clin Cancer Res. 2019 May 14;38(1):194
pubmed: 31088485
Cancer Cell. 2005 Nov;8(5):393-406
pubmed: 16286247
PLoS One. 2016 Feb 22;11(2):e0149743
pubmed: 26901863
J Cell Biochem. 2019 Jun;120(6):9056-9062
pubmed: 30525219
J Clin Oncol. 2014 Dec 20;32(36):4059-65
pubmed: 25403213
Nat Rev Urol. 2016 Dec;13(12):734-752
pubmed: 27804986
Eur Urol. 2018 May;73(5):772-780
pubmed: 29398265
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520
Cancer. 2003 Apr 1;97(7):1663-71
pubmed: 12655523